Pipeline

At Immune Biosolutions, we have developed an internal pipeline to help us focus on the discovery of the future.

IBIO301

Indication: Immuno-oncology
Target: LILRB1/2
Development Partner: Out-Licensing

STAGE

Discovery
100%
Pre-Clinical
10%
Phase 1
0%
Phase 2
0%

IBIO401

Indication: Pediatric Leukemia
Target: TCR mimic
Development Partner: Partnered, Undisclosed

STAGE

Discovery
85%
Pre-Clinical
0%
Phase 1
0%
Phase 2
0%